Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein

Eur J Clin Pharmacol. 2016 Nov;72(11):1413-1414. doi: 10.1007/s00228-016-2107-0. Epub 2016 Jul 26.

Authors

B Clarivet¹, P Robin², Y M Pers³, R Ferreira³, J Lebrun², C Jorgensen³, D Hillaire-Buys², V Brés², J L Faillie²

Affiliations

¹ Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France. [email protected].
² Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France.
³ Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Montpellier University Hospital, Montpellier, France.

PMID: 27457374
DOI: 10.1007/s00228-016-2107-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
Antibodies, Monoclonal, Humanized / pharmacokinetics
Antibodies, Monoclonal, Humanized / therapeutic use*
Anticoagulants / pharmacokinetics
Anticoagulants / therapeutic use*
Antirheumatic Agents / pharmacokinetics
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy
Atrial Fibrillation / drug therapy
Cytochrome P-450 Enzyme System / metabolism
Dabigatran / pharmacokinetics
Dabigatran / therapeutic use*
Drug Interactions
Female
Humans
Mesenteric Ischemia / etiology*
Middle Aged
Receptors, Interleukin-6 / antagonists & inhibitors
Receptors, Interleukin-6 / immunology

Substances

ATP Binding Cassette Transporter, Subfamily B, Member 1
Antibodies, Monoclonal, Humanized
Anticoagulants
Antirheumatic Agents
Receptors, Interleukin-6
Cytochrome P-450 Enzyme System
tocilizumab
Dabigatran